Additionally, measures to control metabolic syndromes—such as using GLP-1 receptor agonists to manage diabetes and statins to regulate blood lipids—have contributed to slowing NAFLD progression and reducing NAFLD-related mortality [32]. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.